Even though the underlying mechanisms of thrombosis risk in cancer is only partly known, tissue factor (TF), cancer cell-derived microvesicles (MV), and podoplanin, a sialoglycoprotein upregulated in several cancer cells able to induce platelet activation, are important actors in the pathophysiology of cancer-related VTE. The gene discussed is F3; the disease is cancer.